Company intelligence / Profile preview

Cetya Therapeutics

Fort Collins, Colorado, United Statescetya-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cetya Therapeutics has developed over 30 largazole analogs with best-in-class profiles as HDACi. Their lead compound CT-101 for sickle cell disease has shown improved performance versus existing therapies in preclinical studies, elevating fetal hemoglobin to higher levels than hydroxyurea while minimizing toxicity and side effects.

Therapeutic areas: HematologyOncologyNeurologyInfectious Diseases
Modalities: Small moleculesHistone deacetylase inhibitors (HDACi)
Industry: Biotech

Drug pipeline

2 assets

CT-101

Pre-clinical

Indications: Sickle cell disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cetya Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cetya Therapeutics.

Explore the full profile